Clinical Trials Logo

Clinical Trial Summary

This is a proof-of-concept study designed to demonstrate whether increases in cerebral blood flow, improvements in brain functioning, and reductions in symptomology associated with traumatic brain injury (TBI) can result from treatments consisting of near-infrared phototherapy (NIR).


Clinical Trial Description

The incidence of traumatic brain injury is widespread. The Centers for Disease Control estimate that 1.7 million TBIs occur each year and that TBI is a contributing factor in about 30% of all injury-related deaths. In addition, about 75% of these TBIs are concussions, or mild TBIs (mTBI). However, such concussions, especially multiple concussions that occur over time, are not harmless. The damage of even mild TBI can potentially lead to neuropsychiatric sequelae. Moreover, injury to the brain can worsen over time depending on the degree of inflammatory response and the areas of injury. TBI induces a number of neuropathological changes like aggregation of beta amyloid and tau proteins along with neuroinflammatory changes that resemble the pathology of degenerative diseases.

For many of our returning Veterans, improvised explosive devices (IEDs) have been the cause of these TBIs. For example, data from the Defense Manpower Data Center indicates that as of October 3, 2011, explosive devices have been responsible for an estimated two-thirds or more of the battlefield injuries in Iraq; of the 46,532 warriors wounded in Operations Enduring Freedom and Iraqi Freedom, 30,347 were wounded by explosive devices, many of which were IEDs. Most of these injuries involved concussive brain injury. While current estimates are that 15-19% of all returning Warfighters have a history of acute concussion or TBI during their tour(s) of duty. It has been noted that "22.8% of a Brigade Combat Team returned from Iraq with confirmed deployment-acquired traumatic brain injury."

Currently, there are no effective treatments for reversing or reducing the brain damage following TBI. Confounding the situation further, the symptoms of TBI can often overlap with those of post-traumatic stress disorder (PTSD) such as headache, dizziness, irritability, memory impairment, delayed problem solving, slowed reaction time, fatigue, visual disturbances, sleep disturbances, sensitivity to light and noise, impulsivity, judgment problems, emotional outbursts, depression, and anxiety. In addition, the rates of depression, anxiety, and other psychological symptoms are markedly elevated in TBI survivors, based on studies involving large samples of patients. As a result of this complexity and overlap of symptoms between TBI, PTSD, and depression, a clear diagnosis of TBI can be challenging, which can lead to misdirected treatment efforts and hamper the ability to accurately assess treatment response.

Multiple published research studies have validated the healing mechanisms of NIR, which can be delivered via light-emitting diodes (LED). NIR phototherapy has been used extensively for wound healing of soft tissue, for increasing circulation, for the treatment of pain and for specific conditions such as hair growth and carpal tunnel syndrome.

The mechanism of action that is central to the healing effect of NIR is increased blood circulation via the release of nitric oxide from red blood cells. Local increases in nitric oxide increase blood flow through arteries, veins and lymphatic ducts. Increased return of flow from treated sites helps to diminish intracellular acidosis that could alter mitochondrial membrane potential(s). This hypothesis holds that when blood flow is adequate, it provides a sufficient amount of oxygen and glucose to cells for adenosine triphosphate (ATP) generation by mitochondria. However, even a modest decrease in regional or global blood flow in the brain, such as that seen in TBI, will limit the amount of glucose and oxygen delivered to neurons. Restoring blood flow levels in damaged regions of the brain thus restores the necessary levels of glucose and oxygen required for ATP generation and proper neuronal functioning.

In addition, nitric oxide stimulates angiogenesis and increased numbers of capillaries will aid in increasing blood flow (and oxygen and glucose) in injured areas of the brain where blood flow was subnormal. This effect contributes to enhanced mitochondrial function. The 1998 Nobel Prize for physiology was awarded to Furchgott, Ignarroand, and Murad for their discovery that nitric oxide acts as a signaling molecule and activates an enzyme, guanylate cyclase (GC), which is necessary for subsequent vasodilation.

Finally, nitric oxide is an effective analgesic; it appears to reduce pain either by reversing local ischemia or directly in a manner akin to the analgesic effect of morphine. In the latter case, nitric oxide helps to regulate membrane potential via alterations in the activity of the ATP dependent potassium channel. This effect may be mediated by activated GC and subsequent phosphorylation of the potassium channel.

Due to its capacity to non-invasively penetrate the skull, NIR has been safely used since the late 1970s for the determination of cerebral blood flow and oxygen levels in brain injured adults, post-stroke patients, and in pediatric patients. Furthermore, transcranial NIR has been shown to increase cortical perfusion and is associated with clinical improvement in human subjects with traumatic brain injury, neurodegenerative disease, and depression. The NIR device for this study is FDA cleared (510K; K101894) for increasing circulation and reducing pain. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02635516
Study type Interventional
Source Cerehealth Corp.
Contact
Status Completed
Phase N/A
Start date April 2014
Completion date April 2015

See also
  Status Clinical Trial Phase
Recruiting NCT04526639 - VR Cognitive Rehabiliation for Pediatric TBI N/A
Recruiting NCT05943756 - Evaluation of Well-being Interventions in Adults With TBI N/A
Completed NCT01339702 - The EPIC Project: Impact of Implementing the EMS Traumatic Brain Injury Treatment Guidelines
Completed NCT00760734 - Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD) Phase 1
Not yet recruiting NCT06024122 - Brain Development in Young Children Following Mild Traumatic Brain Injury - Pilot Study
Completed NCT03896789 - Pediatric Guideline Adherence and Outcomes- Argentina N/A
Completed NCT03225768 - Guided Training for People With Cognitive Impairment N/A
Completed NCT04590911 - Effectiveness of Multimodal Cognitive Rehabilitation for Traumatic Brain Injury Sustained During Older Adulthood N/A
Recruiting NCT04121780 - Growth Hormone Replacement Therapy for Retried Professional Football Players Phase 2
Completed NCT04776304 - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms N/A
Completed NCT00409058 - Teen Online Problem Solving (TOPS) - An Online Intervention Following TBI N/A
Completed NCT00205491 - Pharmacological Intervention in Depression After Traumatic Brain Injury Phase 4
Completed NCT03490110 - Brain Markers of Improvements in Cognitive Functioning N/A
Active, not recruiting NCT02525432 - Autologous Stem Cell Study for Adult TBI (Phase 2b) Phase 2
Completed NCT02858544 - Concussion in Motor Vehicle Accidents: The Concussion Identification Index N/A
Completed NCT01728831 - Study of Cerebral Tissue Oxygenation During Transfusion in Traumatic Brain Injury N/A
Recruiting NCT06005194 - InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI N/A
Not yet recruiting NCT05340803 - Sedation of Ventilated Traumatic Brain Injury Patients With Midazolam Alone Versus Combination With Dexmedetomidine or Magnesium Sulfate; Monitored by Ultrasonograghic Optic Nerve Sheath Diameter Phase 3
Recruiting NCT06195345 - Individual Cerebral Hemodynamic Oxygenation Relationships (ICHOR 1)
Recruiting NCT04279431 - Follow-up of mTBI Patients Discharged From the ED Using Standard Clinical Triage Including BrainScope One